СУЧАСНІ ПОГЛЯДИ НА ПАТОГЕНЕЗ ТА ЛІКУВАННЯ ЦЕНТРАЛЬНОЇ СЕРОЗНОЇ ХОРІОРЕТИНОПАТІЇ (ОГЛЯД ЛІТЕРАТУРИ)

M.A. Karliychuk, I.V. Konovalets

Анотація


В огляді літератури проведено аналіз сучасних поглядів на патогенез та лікування гострої та хронічної форм центральної серозної хоріоретинопатії. Огляд літератури засвідчив відсутність єдиної точки зору та суперечливість існуючих підходів до лікування гострих та хронічних форм даного захворювання, що підтверджує актуальність проблеми та важливість її подальшої розробки для визначення максимально ефективної лікувальної тактики.


Ключові слова


центральна серозна хоріоретинопатія; патогенез; лікування

Повний текст:

PDF

Посилання


Heimann H, Kellner U, Foerster MN, editors Astahova JuS. Atlas po angiografii glaznogo dna. MEDpress-inform.; 2008. 197 c.

Vit VV. Stroenie zritel'noj sistemy cheloveka. Astroprint; 2003. 664 s.

Gacu MV. Fotodinamicheskaja terapija – metod vybora pri lechenii hronicheskih form central'noj seroznoj retinopatii. Materialy IV Vserossijskogo seminara «Kruglyj stol» «Makula-2010»: sb. nauch. tr. –Rostov-na-Donu; 2010, p. 427-429.

Gacu MV, Iskenderova NG. Jatrogennye oslozhnenija nadporogovoj lazerkoaguljacii pri lechenii central'noj seroznoj horioretinopatii. Materialy III Vserossijskogo seminara – «Kruglyj stol» «Makula- 2008»: sb. nauch. tr. – Rostov-na-Donu; 2008, p. 92-94.

Bezdіtko PA, Lagorzhevs'ka ІM, Zavoloka OV. Klіnіchna ocіnka efektivnostі eradikacіjnoї terapії zbudnika Helicobacter pylory u lіkuvannі hvorih na hronіchnu central'nu seroznu horіoretinopatіju. Oftal'mol zh. 2015;3(464):30-35.

Sidorova MV. Central'naja seroznaja horioretinopatija: klinika, diagnostika i lechenie. Oftal'mologija Vost Evropa. 2014;3(22):162-174.

Balashevich LI, Gacu MV, Kasimov JeM i dr. Sovremennye predstavlenija ob jetiologii i patogeneze central'noj seroznoj horioretinopatii. Oftal'mohirurgija. 2007;2:63-67.

Klepinina OB, Pedanova EK, Solomin VA i dr. Central'naja seroznaja horioretinopatija: jetiologija i patogenez. Prakt med. 2012;4(59)2:68-70.

Shhuko AG, Zlobina AN, Jur'eva TN. Jetiopatogeneticheskie podhody k diagnostike i lecheniju ostroj i hronicheskoj central'noj seroznoj horioretinopatii. Obzor literatury . Oftal'mol zh. 2013;2:14-19.

Balashevich LI, Gacu MV, Bajbo-rodov JaV. Jeffektivnost' intravitreal'nogo vvedenija avastina pri lechenii hronicheskih form central'noj seroznoj retinopatii. Materialy IV Vserossijskogo seminara – «Kruglyj stol» «Makula-2010»: sb. nauch. tr. – Rostov-na-Donu. 2011; p. 414-416.

Balashevich LI, Gacu MV, Iskenderova NG. Jeffektivnost' diodnoj subporogovoj mikroimpul'snoj lazerkoaguljacii pri lechenii razlichnyh form central'noj seroznoj retinopatii. Materialy IV Vserosijskogo seminara – «Kruglyj stol» «Makula-2010»: sb. nauch. tr. – Rostov-na-Donu. 2011;p. 416-418.

Caccavale A, Imparato M, Romanazzi F et al. A new strategy of treatment with low-dosage acetyl salicylic acid in patients affected by central serous chorioretinopathy. Med Hypotheses. 2009;73(3):435-437.

Torres-Soriano ME, García-Aguirre G, Kon-Jara V. A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol. 2008;246 (9):1235–1239.

Pikkel J, Beiran I, Ophir A et al. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723-1725.

Alomran MS. Intravitreal bevacizumab for the treatment of central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2010;2:1-3.

Moschos M, Brouzas D, Koutsandrea C et al. Assesment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography. Ophthalmologica. 2007;221:292-298.

Aydin E. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy. J Ocul Pharmacol.Ther. 2013;29(1):10-13.

Cassel GH, Brown GC. Central serous chorioretinopathy: a seasonal variation? Br J Ophthalmol. 1984;68;724-726.

Wang M, Munch IC, Hasler PW et al. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145.

Michael JC, Pak J, Pulido J et al. Central serous chorioretinopathy associated with administration of sympatho mimetic agents. Am J Ophthalmol. 2003;136:182-185.

Ezra N, Taban M, Behroozan D. Central serous chorioretinopathy associated with topical corticosteroids in a patient with psoriasis. J Drugs Dermatol. 2011;10:918-921.

Asensio-Sanchez VM, Rodriguez-Delgado B, GarciaHerrero E et al. Central serous chorioretinopathy as an extradigestive manifestation of Helicobacter pylori gastric infection. Arch Soc Esp Oftalmol. 2008;83:177-182.

Cotticelli L, Borrelli M, D'Alessio AC et al. Central serous chorioretinopathy and Helicobacter pylori. Eur J Ophthalmol. 2006;16:274-278.

Caccavale A, Romanazzi F, Imparato M et al. Сentral serous chorioretinopath: a pathogenetic model. Clin Ophthalmol. 2011;5:239-243.

Bouzas EA, Scott MH, Mastorakos G et al. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol. 1993;111:1229-1233.

Chan WM, Lam DSC, Lai TY et al. Choroidal vascular remodeling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453-1458.

Ravage ZB, Packo KH, Creticos CM et al. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Br Rep. 2012; (1):129-132.

Cioboata M, Alexandrescu C. New treatment approach - Eplerenone - in central serous chorioretinopathy. J Med Life. 2016;9(1):92-94.

Cakir B, Fischer F, Ehlken C et al. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016;245(11):2154-2157.

Türkcü FM, Yüksel H, Sahin A. Effects of smoking on visual acuity of central serous chorioretinopathy patients. Cutan Ocul Toxicol. 2014;33(2):115-119.

Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110:698-703.

Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy. Ophthalmologica. 2001;215:183-187.

Gruszka A. Potential involvement of mineralocorticoid receptor activation in the pathogenesis of central serous chorioretinopathy: case report. Eur Rev Med Pharmacol Sci. 2013;17(10):1369-1373.

Hadcock JR, Malbon CC. Regulation of beta-adrenergic receptors by «permissive» hormones: glucocorticoids increase steadystate levels of receptor mRNA. Proc Nat Acad Sci. 1988;185:8415-8419.

Huang WC, Chen WL,. Tsai YY et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eye. 2009;23:488-489.

Lim SJ, Roh MI,. Know OW. Intravitreal bevacizumab injection for central serous chorioretinopathy. Retina. 2010;30(1):100-106.

Jampol LM, Weinreb R, Yannuzzi L. Involvement of corticoseroids and catecholamines in the pathogenesis of central serous chorioretinopathy: A rationale for new treatment strategies. Ophthalmology. 2002;109:1765-1766.

Giudice GLo, Belvis V, Tavolato M et al. Large-spot subthreshold transpupillary thermotherapy for chronic serous macular detachment. Clin Ophthalmol. 2011;5:355-360.

Caccavale A, Romanazzi F, Imparato M et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899-903.

Marwan A. Advances in the treatment of central serous chorioretinopathy. J Ophthalmol. 2015;29(4):278-286.

Maier M, Stumpfe S, Feucht N et al. Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe.2014;111(2):173-180.

Iida T, Kishi S, Hagimura N. et al. Persistent and bilateral choroidal vascular abnormalities in central serous chorioretinopathy. Retina. 1999;19:508-512.

Nelson J, Saggau DD,. Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Br Rep. 2014;8(1):70-72.

Chan WM,. Lai TY, Lai RY et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28:85-93.

Casalino G, Del Turco C,. Corvi F et al. Short-Term Retinal Sensitivity and Metamorphopsia Changes following Half-Fluence Photodynamic Therapy in Central Serous Chorioretinopathy. Ophthalmic Res. 2016;56(1):23-29.

Tittl MK, Spaide RF, Wong D et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128:63-68.

Conrad R, Geiser F, Kleiman A et al. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. Sci World J. 2014:631-687.

Mudvari SS, Goff MJ, Fu AD. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168-1173.

Tittl MК, Polska E, Kircher K et al. Topical fundus pulsation measurement in patients with active central serous chorioretinopathy. Arch Ophthalmol. 2003;121:975-978.

Hussain N, Khanna R, Hussain A et al. Transpupillary thermotherapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(8):1045-1051.

Chrapek O, Jirkova B, Kandrnal V et al. Treatment of central serous chorioretinopathy with betablocker metipranolol. Olomouc Czech Repub. 2013:3-6.

Yannuzzi LA. Type-A behaviorandcentralserouschorioretinopathy. Retina. 1987;7:111-131.


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24061/2413-0737.XXI.2.82.2.2017.78

Copyright (c) 2017 M.A. Karliychuk, I.V. Konovalets

Технічний редактор журналу, к.мед.н. М. Степанченко, 2015-2017